New BDSI data cuts time against breakthrough pain

Researchers say a new analysis of BioDelivery Sciences International's pain patch Bema Fentanyl shows the therapy demonstrated statistically significant results against breakthrough pain in half the time demonstrated in an earlier analysis. Last month the company said that the patch achieved significant results in 30 minutes, but researchers say that it was able to reduce breakthrough pain in 15 minutes. BDSI is preparing to file a marketing application for the patch in the third quarter and says sales should peak at $250 million.

- here's the AP report on the new data

Suggested Articles

Silverback Therapeutics reeled in $85 million to advance its lead antibody-drug conjugate through the clinic and develop its earlier-stage pipeline.

The reported requirements suggest a company is unlikely to have the data needed to support an EUA before the election in six weeks.  

Blocking tau appears to be just as fruitless as clearing amyloid buildup when it comes to helping Alzheimer’s disease patients.